More than a month after the launch of the new iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program, the operation still isn't running smoothly for many dermatologists, pharmacists, and ...

The US Food and Drug Administration (FDA) is convening an emergency meeting today with representatives from the American Academy of Dermatology Association (AADA) to discuss the flawed rollout of the ...

Please provide your email address to receive an email when new articles are posted on . Researchers, along with the American Academy of Dermatology, have organized an iPLEDGE Workgroup to advocate for ...

In a nod toward transgender inclusiveness, the FDA revised the iPLEDGE risk-modification program for isotretinoin by rewording the reproductive categories for patients. Beginning December 13, patients ...

Please provide your email address to receive an email when new articles are posted on . Pregnancies, abortions and fetal defects associated with isotretinoin exposure continue to be a problem even ...

A risk evaluation and mitigation strategy (REMS) for the use of isotretinoin to treat severe acne is still very much needed, but there are ways to lighten its burden on patients and providers, ...

Dermatologists are renewing their concerns that efforts to prevent pregnant women from using a drug that can cause birth defects may also keep the drug from patients who need it for severe acne. The ...